Simulated human serum profiles of one daily dose of ceftriaxone plus netilmicin in treatment of experimental streptococcal endocarditis

Détails

ID Serval
serval:BIB_BFDE663D1671
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Simulated human serum profiles of one daily dose of ceftriaxone plus netilmicin in treatment of experimental streptococcal endocarditis
Périodique
Antimicrobial Agents and Chemotherapy
Auteur(s)
Blatter  M., Fluckiger  U., Entenza  J., Glauser  M. P., Francioli  P.
ISSN
0066-4804 (Print)
Statut éditorial
Publié
Date de publication
09/1993
Volume
37
Numéro
9
Pages
1971-6
Notes
Journal Article --- Old month value: Sep
Résumé
We performed experiments in rats aimed at determining whether a combination of ceftriaxone (CRO) and netilmicin (NET), by using once-daily administration in rats, which simulated profiles of drug in human serum, was more effective than either agent alone in the treatment of endocarditis caused by viridans group streptococci. A programmable infusion pump system enabled the production of profiles of CRO in serum that simulate those found in humans after the intravenous administration of 2 g. The subcutaneous administration of 18 mg of NET per kg of body weight produced levels in the sera of rats comparable to those after the intravenous administration of a dose of 5 mg of NET per kg in humans. Rats with catheter-induced aortic vegetations were infected intravenously with two test strains, a CRO-susceptible Streptococcus sanguis strain (MICs of CRO and NET, 0.064 and 8 mg/liter, respectively) and a relatively CRO-resistant Streptococcus mitis strain (MICs of CRO and NET, 2 and 8 mg/liter, respectively). Against both strains, the combination of CRO and NET was synergistic in vitro as determined by time-kill curves. Treatment of rats was started 48 h postinfection and lasted for 3 days. CRO alone was effective against the susceptible strain (P < 0.001 compared with control animals) but was not effective against the resistant organism. A significantly enhanced antibacterial activity of the CRO-NET combination in reducing the valvular bacterial counts was observed with both test strains (P < 0.001). The synergistic effect was obtained with a single daily injection of NET which provided detectable levels in serum for only 8 h, suggesting that in vivo synergism in the treatment of infections caused by viridans group streptococci can be obtained without 24 h of aminoglycoside coverage. These experimental data might provide a rationale for clinical trials of a once-a-day dosing regimen in the treatment of streptococcal but nonenterococcal endocarditis.
Mots-clé
Animals Ceftriaxone/administration & dosage/*blood/*therapeutic use Endocarditis, Bacterial/*blood/*drug therapy/microbiology Female Humans Infusion Pumps Microbial Sensitivity Tests Netilmicin/administration & dosage/*blood/*therapeutic use Rats Rats, Wistar Serum Bactericidal Test Streptococcal Infections/*blood/*drug therapy/microbiology Streptococcus/drug effects Streptococcus sanguis/drug effects
Pubmed
Web of science
Création de la notice
24/01/2008 14:45
Dernière modification de la notice
03/03/2018 21:04
Données d'usage